B7-H3 Targeted Therapy Risvutatug Rezetecan Reduces Risk of Death by 54% in Relapsed Small-Cell Lung Cancer

The trajectory of extensive-stage small-cell lung cancer is almost entirely decided at the moment of first relapse. Once the tumor evades initial platinum-based chemotherapy, it typically returns with aggressive resistance, leaving patients and oncologists with few effective secondary options. Overcoming this specific post-platinum bottleneck is the primary hurdle in extending life, as standard second-line chemotherapy often caps median survival at less than a year. Because the cancer cells multiply so rapidly, the window to intervene with a second-line treatment is incredibly narrow, and historical attempts to introduce new agents at this stage have frequently ended in clinical failure. For decades, the oncology community has searched for a mechanism that can bypass this resistance and deliver a lethal blow to the tumor without overwhelming the patient's already compromised system.[6]

A new targeted therapy has now substantially breached that barrier, offering a more reassuring outlook for patients facing a relapse. In the Phase 3 ARTEMIS-008 trial, the antibody-drug conjugate risvutatug rezetecan (Ris-Rez) reduced the risk of death by 54% compared to the standard chemotherapy topotecan. The data, presented at the 2026 World Conference on Lung Cancer in Seoul, marks the first time a B7-H3-directed antibody-drug conjugate has demonstrated an overall survival benefit in a late-stage trial. "These results add to the growing body of evidence for ris-rez and mark an important step forward for our lung cancer portfolio," said Hesham Abdullah, GSK's global head of oncology research and development. The findings suggest that precision medicine can finally be applied to a cancer type that has long resisted targeted interventions.[1][2][3][5]

The survival extension provides a meaningful shift in expectations for this heavily pretreated population. Patients receiving Ris-Rez lived a median of 18.5 months, compared to 10.3 months for those assigned to topotecan. The drug also more than doubled median progression-free survival—the time patients live without their cancer worsening—pushing it to 7.2 months versus 3.0 months for the chemotherapy control arm. In the context of relapsed small-cell lung cancer, where survival improvements are typically measured in weeks rather than months, an eight-month extension in median overall survival represents a fundamental change in the disease's prognosis. It allows patients significantly more time with their families and a longer period of disease stability before further interventions are required.[1][2][4][5]

Ris-Rez operates by targeting B7-H3, a transmembrane protein that is highly expressed on the surface of small-cell lung cancer cells but rarely found on healthy tissue. The drug acts as a guided delivery system: a fully human monoclonal antibody binds to the B7-H3 receptor, allowing the attached payload—a topoisomerase I inhibitor—to enter the tumor cell and destroy its DNA without indiscriminately attacking healthy cells. This mechanism bypasses the traditional resistance pathways that tumors use to block standard platinum-based chemotherapy. By using the cancer's own surface proteins against it, the antibody-drug conjugate ensures that the cytotoxic payload is concentrated exactly where it is needed most, maximizing tumor cell death while attempting to spare the surrounding healthy organs from collateral damage.[1][5]

This targeted mechanism translated to a dramatic increase in tumor shrinkage, giving patients a higher chance of stabilizing their disease. According to an independent review committee, 58.3% of patients on Ris-Rez experienced an objective response, compared to just 12.6% on topotecan. The overall disease control rate reached 90.4% for the targeted therapy cohort, meaning the vast majority of patients saw their cancer either shrink or stop growing. For a patient facing a rapidly advancing relapse, achieving disease control is the critical first step in regaining quality of life. The high response rate indicates that the B7-H3 target is consistently present and vulnerable across the patient population, making it a highly reliable avenue for intervention.[5]

For patients weighing the physical toll of further treatment, the targeted delivery system resulted in fewer severe side effects than traditional chemotherapy. Grade 3 or higher treatment-related adverse events occurred in 60.9% of patients on Ris-Rez, compared to 78.2% on topotecan. The most common severe toxicities for the experimental drug were hematologic, including anemia and decreased white blood cell counts, which clinical teams can typically manage with supportive care. Importantly, the trial reported no fatal instances of interstitial lung disease, a severe inflammatory condition that has complicated the development of other antibody-drug conjugates in this class. The improved safety profile means patients are more likely to tolerate the full course of treatment without requiring dose reductions or early discontinuation.[5]

The 18.5-month survival figure alters the competitive landscape for second-line treatments, providing a benchmark against other emerging therapies. Amgen's T-cell engager Imdelltra recently posted a 13.6-month median overall survival in its own Phase 3 trial, while Merck and Daiichi Sankyo are advancing a rival B7-H3 targeted drug, ifinatamab deruxtecan, which showed a 12.0-month median survival in Phase 2 data. While cross-trial comparisons are inherently flawed due to differing patient populations and trial designs, the sheer magnitude of the Ris-Rez survival curve establishes a formidable new standard. Pharmaceutical competitors advancing their own targeted therapies will now have to demonstrate that their drugs can either match this 18.5-month benchmark or offer a substantially better safety profile to remain viable options in the second-line setting.[4]

However, patients and clinicians must navigate one key layer of uncertainty: the trial's geography. The study, sponsored by GSK's partner Hansoh Pharma, enrolled all 461 of its patients at clinical sites in China. GSK, which holds the global rights to Ris-Rez outside of greater China, is currently running a parallel global Phase 3 trial, EMBOLD SCLC-301, to confirm whether these survival figures replicate across broader international populations. Regulatory agencies like the US Food and Drug Administration have historically required diverse, multi-regional data before approving new cancer therapies, meaning the ARTEMIS-008 results alone will not immediately change prescribing guidelines in Western countries. The oncology community will closely monitor the global trial to ensure the drug's efficacy holds up across different genetic backgrounds and clinical care standards.[4][5]

Hansoh Pharma plans to use the ARTEMIS-008 data to support a regulatory submission in China, where the National Medical Products Administration has already granted the application Priority Review. For patients in the United States and Europe, access will depend on the global EMBOLD data expected in 2027, which will ultimately determine whether Ris-Rez becomes the new standard of care for relapsed small-cell lung cancer. Until then, the results from Seoul offer a powerful proof of concept that the post-platinum bottleneck can be broken. The data provides genuine reassurance that the next generation of targeted therapies is finally catching up to one of the most aggressive and historically untreatable forms of lung cancer.[1][4]